Literature DB >> 27805602

Surgical Approach for Middle Cerebral Artery Occlusion and Reperfusion Induced Stroke in Mice.

Shantel A Vital1, Felicity N E Gavins2.   

Abstract

Stroke is a leading cause of death worldwide and continues to be one of the major causes of long-term adult disabilities. About 87% of strokes are ischemic in origin and occur in the territory of the middle cerebral artery (MCA). Currently the only Food and Drug Administration (FDA) approved drug for the treatment of this devastating disease is tissue plasminogen activator (tPA). However, tPA has a small therapeutic window for administration (3 - 6 hr), and is only effective in 4% of the patients who actually receive it. Current research focuses on understanding the pathophysiology of stroke in order to find potential therapeutic targets. Thus, reliable models are crucial, and the MCA occlusion (MCAo) model (also termed the intraluminal filament or suture model) is deemed to be the most clinically relevant surgical model of ischemic stroke, and is fairly non-invasive and easily reproducible. Typically the MCAo model is used with rodents, especially with mice due to all the genetic variations available for this species. Here we describe (and present in the video) how to successfully perform the MCAo model (with reperfusion) in mice to generate reliable and reproducible data.

Entities:  

Mesh:

Year:  2016        PMID: 27805602      PMCID: PMC5092223          DOI: 10.3791/54302

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  29 in total

1.  Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse.

Authors:  Valentine Bouët; Thomas Freret; Jérôme Toutain; Didier Divoux; Michel Boulouard; Pascale Schumann-Bard
Journal:  Exp Neurol       Date:  2006-10-24       Impact factor: 5.330

Review 2.  Assessing post-stroke behavior in mouse models of focal ischemia.

Authors:  Mustafa Balkaya; Jan M Kröber; Andre Rex; Matthias Endres
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-12       Impact factor: 6.200

3.  Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

Authors:  Sheila M Fleming; Jonathan Salcedo; Pierre-Olivier Fernagut; Edward Rockenstein; Eliezer Masliah; Michael S Levine; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2004-10-20       Impact factor: 6.167

4.  Behavioral deficits after distal focal cerebral ischemia in mice: Usefulness of adhesive removal test.

Authors:  Thomas Freret; Valentine Bouet; Claire Leconte; Simon Roussel; Laurent Chazalviel; Didier Divoux; Pascale Schumann-Bard; Michel Boulouard
Journal:  Behav Neurosci       Date:  2009-02       Impact factor: 1.912

5.  Mild induced hypertension improves blood flow and oxygen metabolism in transient focal cerebral ischemia.

Authors:  Hwa Kyoung Shin; Masaki Nishimura; Phillip B Jones; Hakan Ay; David A Boas; Michael A Moskowitz; Cenk Ayata
Journal:  Stroke       Date:  2008-03-13       Impact factor: 7.914

6.  Protection of cerebral microvasculature after moderate hypothermia following experimental focal cerebral ischemia in mice.

Authors:  Jan Burk; Dorothe Burggraf; Milan Vosko; Martin Dichgans; Gerhard F Hamann
Journal:  Brain Res       Date:  2008-06-16       Impact factor: 3.252

7.  Effects of hyperthermia on infarct volume in focal embolic model of cerebral ischemia in rats.

Authors:  Raza Noor; Chen Xu Wang; Ashfaq Shuaib
Journal:  Neurosci Lett       Date:  2003-10-02       Impact factor: 3.046

8.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

9.  Developments of a water-maze procedure for studying spatial learning in the rat.

Authors:  R Morris
Journal:  J Neurosci Methods       Date:  1984-05       Impact factor: 2.390

10.  Critical differences between two classical surgical approaches for middle cerebral artery occlusion-induced stroke in mice.

Authors:  Helen K Smith; Janice M Russell; D Neil Granger; Felicity N E Gavins
Journal:  J Neurosci Methods       Date:  2015-04-30       Impact factor: 2.390

View more
  6 in total

1.  Time course images of cellular injury and recovery in murine brain with high-resolution GRIN lens system.

Authors:  Chelsea D Pernici; Benjamin S Kemp; Teresa A Murray
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

2.  Therapeutic effect of transplantation of human bone marrow‑derived mesenchymal stem cells on neuron regeneration in a rat model of middle cerebral artery occlusion.

Authors:  Ping Xie; Ming Deng; Qin-Guo Sun; Yong-Gang Ma; Yan Zhou; Jiang-Hua Ming; Qing Chen; Shi-Qing Liu; Jun-Qi Liu; Jun Cai; Fei Wu
Journal:  Mol Med Rep       Date:  2019-07-30       Impact factor: 2.952

Review 3.  Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke.

Authors:  Kelsy L Nilles; Erica I Williams; Robert D Betterton; Thomas P Davis; Patrick T Ronaldson
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

4.  The construction of neurogenesis-related ceRNA network of ischemic stroke treated by oxymatrine.

Authors:  Xiaoling Zhang; Wentao Yao; Wannian Zhao; Yingru Sun; Zongkai Wu; Weiliang He; Yingxiao Ji; Yaran Gao; Xiaoli Niu; Litao Li; Hebo Wang
Journal:  Neuroreport       Date:  2022-09-07       Impact factor: 1.703

5.  Phytosome Loading the Combined Extract of Mulberry Fruit and Ginger Protects against Cerebral Ischemia in Metabolic Syndrome Rats.

Authors:  Nut Palachai; Jintanaporn Wattanathorn; Supaporn Muchimapura; Wipawee Thukham-Mee
Journal:  Oxid Med Cell Longev       Date:  2020-07-25       Impact factor: 6.543

6.  Memory-Enhancing Effect of a Phytosome Containing the Combined Extract of Mulberry Fruit and Ginger in an Animal Model of Ischemic Stroke with Metabolic Syndrome.

Authors:  Jintanaporn Wattanathorn; Nut Palachai; Wipawee Thukham-Mee; Supaporn Muchimapura
Journal:  Oxid Med Cell Longev       Date:  2020-07-28       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.